References
- Keles GE, Lamborn KR, Berger MS. Low grade hemispheric glioma in adults: a critical review of extent of resection of low grade tumors. J. Neurosurg. 95, 735–745 (2001).
- Karim AB, Maat B, Hatlevoli R et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844. Int. J. Radiat. Oncol. Biol. Phys. 36, 549–556 (1996).
- Karim AB, Afra D, Cornu P et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer study 22845 with the Medical Research Council study BR04-and interim analysis. Int. J. Radiat. Oncol. Biol. Phys. 52, 316–324 (2002).
- Shaw E, Arussel R, Scheithauer B et al. Prospective randomized trial of low versus high dose radiation therapy in adults with supratentorial low grade glioma: initial report of a north central cancer treatment group/radiation therapy oncology group/easter co-operative oncology group study. J. Clin. Oncol. 20, 2267–2276 (2002).
- Surma-aho O, Niemela M, Vilkki J et al. Adverse long-term effects of brain radiotherapy in adult low grade glioma patients. Neurology 56, 1285–1290 (2001).
- Cairncross JG, MacDonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann. Neurol. 23, 360–364 (1988).
- MacDonald DR, Gaspar LE, Cairncross JG. Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann. Neurol. 27, 573–574 (1990).
- Reifenberger G, Louis DN. Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J. Neuropathol. Exp. Neurol. 62(2), 111–126 (2003).
- Sasaki H, Zlatescu MC, Betensky RA et al. Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade ‘oligodendroglioma’. J. Neuropathol. Exp. Neurol. 61(1) 58–63 (2002).
- Cairncross, JG, Ueki K, Zlatescu C et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl. Cancer Inst. 90, 1473–1479 (1998).
- Ino Y, Betensky RA, Zlatescu MC et al. Molecular subtypes of anaplastic oligodendroglioma: Implications for patient management at diagnosis. Clin. Cancer Res. 7, 839–845 (2001).
- Paleologos NA, Vick NA, Kachoris JP. Chemotherapy for low grade gliomas? Ann. Neurol. 36, 294–295A (1994).
- Mason WP, Krol, GS, DeAngelis LM. Low-grade oligodendroglioma responds to chemotherapy. Neurology 46, 203–207 (1996).
- Soffietti R, Ruba R, Borgognone M et al. Chemotherapy with PCV for low grade nonenhancing oligodendrogliomas and oligoastrocytomas. Neurology 52(6 Suppl. 2), A423–A424 (1999).
- Buckner JC, Gesme D JR, O’Fallen JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J. Clin. Oncol. 21(2), 251–255 (2003).
- See SJ, Ty A, Wong MC. Low grade oligodendroglioma and PCV chemotherapy: pictures tell a tale. Neuro-oncol. 6(4), A382 (2004).
- Hoang-Xuan K, Capelle L, Kujas S et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J. Clin. Oncol. 22, 3133–3138 (2004).
- Quinn JA, Reardon DA, Friedman AH et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J. Clin. Oncol. 21, 646–651 (2003).
- Pace A, Vidiri A, Galie E et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann. Oncol. 14, 1722–1726 (2003).
- Brada M, Viviers L, Abson C et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann. Oncol. 14, 1715–1721 (2003).